| Original language | English (US) |
|---|---|
| Pages (from-to) | 670-672 |
| Number of pages | 3 |
| Journal | Kidney Medicine |
| Volume | 2 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2020 |
Bibliographical note
Funding Information:Financial support for this work provided by National Institute of Diabetes and Digestive and Kidney Diseases grants DK116720 , DK076169 , and DK115255 (Dr Bjornstad), JDRF grant number 2-SRA-2018-627-M-B (Dr Bjornstad) and 2-SRA-2019-845-S-B , UL1-RR025780 ( University of Colorado Denver ), support from Center for Women’s Health Research, University of Colorado , the Department of Pediatrics, Section of Endocrinology and Barbara Davis Center for Diabetes at University of Colorado School of Medicine .
Funding Information:
Jesse C. Seegmiller, PhD, Brian J. Wolfe, PhD, Nansy Albtoush, PhD, Isabella Melena, BS, Susan P. Gross, RD, Carisa Vinovskis, MS, Joachim H. Ix, MD, and Petter Bjornstad, MD. Research idea and study design: JCS, JHI, PB; data acquisition: IM, SPG, CV, PB; data analysis/interpretation: JCS, BJW, NA, JHI, PB. JHI and PB contributed equally as last authors. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. Financial support for this work provided by National Institute of Diabetes and Digestive and Kidney Diseases grants DK116720, DK076169, and DK115255 (Dr Bjornstad), JDRF grant number 2-SRA-2018-627-M-B (Dr Bjornstad) and 2-SRA-2019-845-S-B, UL1-RR025780 (University of Colorado Denver), support from Center for Women's Health Research, University of Colorado, the Department of Pediatrics, Section of Endocrinology and Barbara Davis Center for Diabetes at University of Colorado School of Medicine. Disclosure of any potential conflicts of interests: Dr Bjornstad has acted as consultant for Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Novo Nordisk, and Horizon Pharma and serves on the advisory boards of XORTX and Boehringer Ingelheim. Dr Ix is Principal Investigator of an Investigator Initiated Research Grant supported by Baxter Int. Received February 24, 2020. Evaluated by 2 external peer reviewers, with direct editorial input from the Statistical Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form May 20, 2020.
Funding Information:
Disclosure of any potential conflicts of interests: Dr Bjornstad has acted as consultant for Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Novo Nordisk, and Horizon Pharma and serves on the advisory boards of XORTX and Boehringer Ingelheim. Dr Ix is Principal Investigator of an Investigator Initiated Research Grant supported by Baxter Int.